Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Orforglipron

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Eli Lilly · Phase 3 · Active, not recruiting · Enrollment 1400

NCT06993792

ArmPopulationDoseWeeksEstimandWeight change
Orforglipron Dose 1 (Study GZP1)Obesity + T2Dn/r4n/rn/r
Orforglipron Dose 2 (Study GZP1)Obesity + T2Dn/r4n/rn/r
Orforglipron Dose 3 (Study GZP1)Obesity + T2Dn/r4n/rn/r
Orforglipron Dose 4 (Study GZP1)Obesity + T2Dn/r4n/rn/r
Placebo (Study GZP1)Obesity + T2Dn/r4n/rn/r
Orforglipron Dose 1 (Study GZP2)Obesity + T2Dn/r4n/rn/r
Orforglipron Dose 2 (Study GZP2)Obesity + T2Dn/r4n/rn/r
Orforglipron Dose 3 (Study GZP2)Obesity + T2Dn/r4n/rn/r
Orforglipron Dose 4 (Study GZP2)Obesity + T2Dn/r4n/rn/r
Placebo (Study GZP2)Obesity + T2Dn/r4n/rn/r